CROMA-PHARMA
Croma-Pharma (Croma), today announced that the decentralized procedure for its botulinum toxin to gain market authorization in Europe has been accomplished. This important step is the basis to complete Croma’s already comprehensive portfolio.
Croma’s botulinum toxin submission in Europe is based on the data of 3 completed randomized, placebo-controlled phase III trials that enrolled a total of >1000 subjects in Europe and the US. National phases to grant the market authorization across Europe are following now.
A game changer for Croma-Pharma and the aesthetic industry
By adding its own botulinum toxin to the already broad portfolio Croma catapults itself to a new level within the aesthetic industry.
Offering already a wide selection of HA fillers, PDO threads, PRP and scientific skincare products, the botulinum toxin was the missing piece to compete with world leaders in this sector.
“We are pleased to announce that our toxin has now accomplished the decentralized procedure in Europe and will continue with the market authorization in major European countries in the next months. With this, we will now be able to complete our portfolio to meet all the needs of our customers”, Managing Director Andreas Prinz points out.
Partnership with Hugel
Croma has licensed the product from the Korean toxin producer Hugel Inc. for Europe and established a joint venture company in 2018 with Hugel, Inc., in order to develop and commercialize Croma’s HA filler products together with Hugel’s botulinum toxin product in the US, Canada, Australia and New Zealand.
About Croma
Founded in 1976, Croma-Pharma GmbH (Croma) is an Austrian family-owned company that specializes in the industrial production of hyaluronic acid syringes for the fields of medical aesthetics, ophthalmology and orthopaedics. Croma currently runs 12 international sales companies and distributes its products in more than 70 countries. Within its global sales network, Croma focuses with own branded products on minimally invasive aesthetic medicine. Besides a broad range of HA fillers from the own production site, Croma markets PDO lifting threads, a Platelet Rich Plasma (PRP) system and high-quality skincare technologies in its core strategic markets.
About Hugel, Inc.
Established in Korea in 2001, Hugel is a global leader in medical aesthetics providing botulinum toxin formulation under different brand names such as BOTULAX and LETYBO in numerous countries across the world. Dedicated to provide proven, high quality medical aesthetic solutions that satisfy both consumers’ and practitioners’ needs, Hugel is leading the Korean market with its botulinum toxin.
PR2LET0122GMXb
View source version on businesswire.com: https://www.businesswire.com/news/home/20220127005535/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Quectel Unveils Advanced Matter over Thread Modules for Seamless Device Interoperability13.11.2025 10:00:00 CET | Press release
Quectel Wireless Solutions, an end-to-end global IoT solutions provider, today announced the launch of the KGM133S, the first in a range of Matter over Thread modules that provides innovative solutions for applications such as smart door locks, sensors, and lighting, helping the smart home industry overcome connectivity barriers and advance toward a new era of more efficient and seamless development. The KGM133S series modules are built based on the Silicon Labs EFR32MG24 chip, supporting the latest Matter 1.4 protocol. The modules are designed to enable seamless linkage of home devices across ecosystems, including Apple Home, Google Home, Amazon Alexa and Samsung SmartThings. “Protocol fragmentation remains one of the biggest obstacles to seamless smart device connectivity, and the Matter protocol is the key to overcoming it,” said Delbert Sun, Deputy General Manager at Quectel Wireless Solutions. “With our new Matter over Thread modules, we are helping the industry achieve true inter
SBC Medical Group Announces Commencement of Tender Offer for Shares of Waqoo, Inc.13.11.2025 09:57:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that on November 13, 2025, SBC Medical Group Co., Ltd. (the “Tender Offeror”) has resolved to acquire shares of common stock of Waqoo, Inc. (Securities Code: 4937, listed on the Tokyo Stock Exchange Growth Market; the “Target Company”) through a tender offer (the “Tender Offer”) pursuant to the Financial Instruments and Exchange Act of Japan (Act No. 25 of 1948, as amended; the “FIEA”), as described below. The Tender Offeror is a Japanese subsidiary ultimately owned by SBC Medical Group Holdings Incorporated (“SBCHD”), a U.S. corporation listed on NASDAQ and engaged in management support services for medical clinics both domestically and internationally. As of today, the Tender Offeror holds 353,600 shares of the Target Company’s common stock (ownership ratio: 9.49%).
IQM Launches Halocene, a New Quantum Computer Product Line for Error Correction13.11.2025 09:56:00 CET | Press release
IQM Halocene is a new quantum computer product line aimed at error correction development. It will start with a150-qubit system to be delivered by the end of 2026 and extend all the way to 1,000-qubits. The new product line is based on an open and modular error correction stack, which will allow end-users to experiment and run different quantum error correction features. IQM’s goal is to enable users from supercomputing centers, research organizations, and universities to innovate on quantum error correction research with an open platform. IQM has sold more on-premises quantum systems globally than any other manufacturer, and the company expects the new Halocene product line to accelerate its revenue growth further IQM Quantum Computers, a global leader in superconducting quantum computers, today announced the launch of its new product line called IQM Halocene. The new product line is based on open and modular on-premises quantum computers designed for quantum error correction research
JSR Life Sciences Enters Definitive Agreement to Transfer Crown Bioscience to Adicon Holdings Limited13.11.2025 09:45:00 CET | Press release
Strategic Transaction Positions Crown Bioscience for Accelerated Growth in Translational Oncology JSR Life Sciences LLC ("JSR Life Sciences"), a global leader in life sciences materials and services, today announced it has entered into a definitive agreement to transfer Crown Bioscience Inc. ("Crown Bioscience") to Adicon Holdings Limited ("Adicon"), a premier independent clinical laboratory provider in China and a portfolio company of The Carlyle Group. The transaction, subject to customary closing conditions, is expected to close in 2026. This strategic move will enable Crown Bioscience to operate as a standalone entity under Adicon's ownership. Crown Bioscience's comprehensive portfolio of translational oncology services, including its world-leading patient-derived xenograft (PDX) models, tumor organoid platforms, immuno-oncology assays, and bioinformatics solutions, will transition to Adicon, positioning the company to accelerate advancements in precision medicine and drug discover
Ohmium Breaks Barriers: Exceeds 2030 Industry Targets of 10 GW/ton to Achieve 18 GW/ton Iridium Utilization13.11.2025 09:05:00 CET | Press release
Ohmium International Inc., a leading provider of cutting-edge, high-efficiency, and modular Proton Exchange Membrane (PEM) electrolyzers, has surpassed the PEM electrolyzer industry's 2030 target of 10 GW per ton to attain an 18 GW per ton iridium utilization rate. Ohmium has made significant technological advancements which have resulted in reducing its iridium usage by 50% in its Lotus electrolyzer, Mark 2. This enhances the cost-competitiveness of green hydrogen production by reducing the overall cost of its PEM electrolyzers, which have been impacted by the cost of the precious metal, iridium. Dr. Chock Karuppaiah, Ohmium Chief Science and Technology Officer, said, "We've made significant strides in reducing iridium usage in our PEM electrolyzers, exceeding the 2030 industry target of 10 GW per ton. We've achieved a utilization rate of 18 GW per ton. This innovation is crucial, as iridium is one of the most expensive materials in electrolyzer manufacturing.” Dr. Markus Tacke, Ohmiu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom